Chris Hollowood

Chris Hollowood

Chief Executive Officer

Chris is the Chief Executive Officer of Syncona Investment Management Ltd.

He has been instrumental in the foundation and development of Syncona's gene therapy strategy, where it has founded companies focused on the eye, the liver, the kidney, and central nervous system. He is Chairman of Beacon, Freeline, Purespring and Forcefield and was also previously Chairman of retinal gene therapies Nightstar, which was sold to Biogen in 2019 for $877 million, and Gyroscope, which was sold to Novartis for up to $1.5 billion in 2022. 

Previously, Chris was a partner of Apposite Capital LLP, a venture and growth capital healthcare investment company. Before Apposite, Chris had roles with Bioscience Managers Ltd, Neptune Investment Management Ltd and in the pharmaceutical industry. Chris holds a degree in Natural Sciences and a PhD in Organic Chemistry, both from the University of Cambridge.

Syncona portfolio companies

  • Freeline Therapeutics (Chair)
  • Purespring Therapeutics (Chair)
  • Beacon Therapeutics (Chair)
Roel Bulthuis

Roel Bulthuis

Managing Partner, Head of Investments
Rolf Soderstrom

Rolf Soderstrom

Chief Financial Officer
Edward Hodgkin

Edward Hodgkin

Managing Partner
John Tsai

John Tsai

Executive Partner
Alasdair Moodie

Alasdair Moodie

General Counsel
Annabel Clark

Annabel Clark

Head of Corporate Affairs and ESG
Andrew Cossar

Andrew Cossar

Executive Partner, Head of Strategic Transactions
Kate Butler

Kate Butler

Group Finance Director